Jean-Ehrland RICCI

In my role as AE for Oncogenesis, I look for translation potential and solid experimental work in a manuscript. I believe such studies are key to advancing science as well as cancer care.

–Maarten

Delighted to have him on our team at #Oncogenesis! 🤝

But also aim to ascertain efficacy from novel interventions or stratification modalities in early phase clinical studies.

We focus on tumor cell plasticity, the tumor microenvironment, and inter- and intratumor heterogeneity. We apply patient-derived preclinical models, gene expression profiling and wetlab experimental work.

🧬 Meet One of Our Associate Editors: Maarten Bijlsma

I am the scientific director of the Cancer Center Amsterdam, Amsterdam UMC, and professor of Experimental Gastrointestinal Oncology. My group is trying to find out why pancreatic and esophageal cancers are so hard to treat effectively.

Check how their study uncovers a novel cytoplasmic role of BRCA1 in regulating ER-associated protein stability via a non-canonical DNA damage response pathway and highlights mRNA stability and ER calcium signalling as potential therapeutic targets to overcome chemoresistance.

“Non canonical BRCA1 promotes cell survival via modulating PARP13-mediated SEC61G mRNA decay”

🔵 Guo Chen latest research is now available to read in #Oncogenesis.

▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how authors, through the integration of bioinformatics techniques and experimental validation, show that NAC1 activates LDHA expression through transcription and suppresses CD8 + T cells, thus inducing HBV immune escape and ultimately promoting the occurrence of liver cirrhosis and HCC.

"NAC1 transcriptional activation of LDHA induces hepatitis B virus immune evasion leading to cirrhosis and hepatocellular carcinoma development”

🔷Outstanding research from Lisheng Wang is now available to read in #Oncogenesis

▶️Read the full open access article here: www.nature.com/articles/s41...

Check how the ability of ONC201 to overcome cisplatin resistance and its synergistic antitumor effects highlight its promise as a candidate for combination therapy.

“ONC201 enhances the cytotoxic effect of cisplatin through ATF3/ATF4/CHOP in head and neck squamous cell carcinoma cells”

🔵 Interesting research led Ming-Huei Chou has been featured in #Oncogenesis.

▶️ Read the full open access article here: www.nature.com/articles/s41...

“CENPF (+) cancer cells promote malignant progression of early-stage TP53 mutant lung adenocarcinoma”

🔵 Tao Jiang’s groundbreaking research appeared in #Oncogenesis

▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their findings suggest that cancer cells exhibiting high expression of centromere protein F (CENPF) play a central role in orchestrating the malignant evolution of LUAD and hold potential as a novel biomarker for early-stage detection and management of the disease.

Check how the authors uncovered a previously under-characterized role of the SRCAP-1879 truncating mutation in driving multiple aspects of epithelial cancer progression, including invasion.

“A dominant SRCAP truncating mutation promotes squamous cell carcinoma progression”

🔵 Xiaomin Bao latest and outstanding research is now available to read in #Oncogenesis.

▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how these findings elucidate the pivotal role of RIOK3 in the cellular response to glucose deprivation, demonstrating its capacity to enhance IDH1 expression and NADPH generation in an HSP90α-dependent manner.

“RIOK3 sustains colorectal cancer cell survival under glucose deprivation via an HSP90α-dependent pathway”

🔵 Interesting research led by Shengtao Zhu has been featured in #Oncogenesis.

▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their findings indicates that BRG1 regulates PKM2 Y105 phosphorylation and oligomeric state by enhancing the interaction between SHP1 and PKM2, and that BRG1 modulates glycolysis in NSCLC cells through the BRG1/SHP1/PKM2 Y105 pathway.

“BRG1 inhibits glycolysis by promoting SHP1-mediated dephosphorylation of PKM2 in non-small cell lung cancer”

🔷 Haijie Li & Jingqin Lan latest research is now available to read in #Oncogenesis.

▶️ Read the full open access article here: www.nature.com/articles/s41...

👏 Congratulations to Anna for this outstanding achievement, and many thanks to the SA2M community for an inspiring and engaging meeting!

#SA2M2025 #Autophagy #Apoptosis #ResearchPublication #LifeSciences #PosterPrize #Oncogenesis

🏆 We were also delighted to award a #PosterPrize sponsored by @springernature.com - Oncogenesis to Anna Siewerth, PhD student at the Institute of Molecular Medicine and Cell Research, University of Freiburg, for her poster: “Identification of caspase-8 substrates and TNFR1 complex II interactors.”

📢 Our Editor-in-Chief, Jean-Ehrland Ricci (@jer-06.bsky.social), delivered a keynote session entitled “Manuscript Mission: Navigating the Path to Research Publication”, sharing valuable insights into the journey of publishing impactful research.

🔬 Oncogenesis at SA2M 2025 🔬

Oncogenesis was proud to support the Swiss Apoptosis & Autophagy Meeting (SA2M), held on 4–5 September 2025 at the Institute of Pathology, Inselspital, Bern and organized by Life Sciences Switzerland (LS2) - Autophagy

Check how this research offers novel insights into the potential therapeutic applications of Pimozide in cancer treatment, an FDA-approved antipsychotic, as it upregulates peroxisomal lipid-metabolizing enzymes in tumor cells.

“Peroxisomal lipid metabolism inhibits Pimozide-induced cancer cell death by regulating ATP homeostasis”

🔷 Zhenye Yang latest research is now available to read in #Oncogenesis.

▶️ Read the full open access article here: www.nature.com/articles/s41...

Over the years, he has served on numerous editorial boards and international scientific review panels, which has shaped his expertise in multidisciplinary science and being an associate editor.

Delighted to have him on our team at Oncogenesis! 🤝

At the Icahn School of Medicine at Mount Sinai, he leads the development of graduate curriculum focused on cell biology and actively trains the next generation of aspiring biomedical research scientists.

🧬Meet One of Our Associate Editors: Jerry Chipuk, PhD

As a Professor of Oncological Sciences and Associate Director of the Tisch Cancer Institute at MS in NY, his research focuses on how mitochondria dictate fundamental cell biology, impact upon cancer mechanisms, and mediate therapeutic responses.

Check how JMV7048, a novel PXR agonist-based PROTAC, reduces PXR protein expression in drug-tolerant colon cancer cells, sensitizing them to chemotherapy and significantly delaying cancer relapse in xenografted nude mice.

“Targeting pregnane X receptor with a potent agonist-based PROTAC to delay colon cancer relapse”

🔷 Outstanding research from J. Pannequin, W. Bourguet, M. Amblard & JM Pascussi is now available to read in #Oncogenesis.

▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how the results of this research uncover a role of PADI3 in the regulation of sensitivity to neratinib in breast cancer cells overexpressing HER2 and open the possibility of using PADI3 inhibitors to fight resistance to neratinib.